Decera Clinical Education Oncology Podcast

In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance. Presenters:David E. Kaplan, MD, MScAssociate ProfessorPerelman School of MedicineChief, Hepatology Section Division of Gastroenterology and Hepatology University of PennsylvaniaDirector of HepatologyCorporal Michael J. Crescenz VA Medical CenterPhiladelphia, PennsylvaniaTamar Taddei, MDProfessor Section of Digestive Diseases Department of Internal MedicineYale School of Medicine Chief, GI Section VA Connecticut Healthcare SystemWest Haven, Connecticut Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience. Presenter:Zoe LanhamPatientLink to full program:https://bit.ly/3Fukjzk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer  • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test  • Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial  • Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancerPresenters:Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, France  Ignace Vergote, MD, PhDProfessor Em. of Department of Obstetrics and Gynecologic OncologyUniversity Hospitals LeuvenLeuven, BelgiumContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include:4 aspects of transgender care: emotional, social, medical, legalGetting language right and how to gracefully recover from fumblesSensitively approaching ongoing cancer care in transmasculine and transfeminine individualsHandling billing and charting challenges when caring for transgender patientsIdeas for institutional change to improve healthcare for transgender individualsPresenters:Yee Won ChongCo-filmmaker, Trans Dudes with Lady CancerSenior Fellow, Racial EquityWestern States CenterEquity, Diversity, and Inclusion Strategist and ConsultantPortland, OregonNorma Steiner, MDGynecological OncologistNorthwest PermanentePortland, OregonLink to full program:http://bit.ly/3Ugz0LR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial todayRelevance of overall response rate vs progression-free survival for BTK inhibitor therapyApproval of ibrutinib/venetoclax combination therapy for patients with CLLKey differences between zanubrutinib and acalabrutinib in the treatment of patients with CLLHow to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitorFaculty:Farrukh T. Awan, MDAssociate Professor of Internal MedicineDirector of Lymphoid Malignancies ProgramHarold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallas, TexasNicole Lamanna, MDAssociate ProfessorLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical CenterNew York, New YorkLink to the complete program, including downloadable slidesets and an on-demand webcast:https://bit.ly/3EjvSKm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor)Presenters:Christopher R. Flowers, MD, MSDepartment Chair, Department of Lymphoma/MyelomaDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer Center Houston, TexasKami Maddocks, MDProfessor of Clinical Internal MedicineDivision of Internal MedicineDepartment of HematologyThe Ohio State UniversityLymphoma Program DirectorThe Ohio State University James Cancer HospitalColumbus, Ohio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:How to sequence currently available therapies after relapseChallenges with using BCMA-targeted agents in clinical practiceExperts’ thoughts on the potential approval of bispecific agentsPresenters include:Paul G. Richardson, MDRJ Corman Professor of MedicineHarvard Medical SchoolClinical Program LeaderDirector of Clinical ResearchJerome Lipper Multiple Myeloma CenterDana Farber Cancer InstituteBoston, MassachusettsNatalie S. Callander, MDProfessor of MedicineSchool of Medicine and Public HealthUniversity of WisconsinDirectorMyeloma Clinical ProgramUniversity of Wisconsin Carbone Cancer CenterMadison, WisconsinNoopur Raje, MDDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsContent for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc.Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3Fc7eMK Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancerPhase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancerPhase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancerRetrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervixPresenters:Susana Banerjee, MBBS, MA, PhD, FRCPConsultant Medical Oncologist and Research LeadGynaecology UnitRoyal Marsden NHS Foundation TrustLondon, United KingdomMansoor Raza Mirza, MDChief OncologistDepartment of OncologyRigshopitalet – Copenhagen University HospitalCopenhagen, DenmarkContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/38xuRBv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including:Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placeboPhase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced ovarian cancerPhase III ATHENA-MONO: outcomes by disease subgroups receiving rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancerPhase III ARIEL4: OS outcomes following treatment with rucaparib vs chemotherapy in patients with relapsed advanced ovarian cancer and a deleterious BRCA1/2 mutationPresenters:Domenica Lorusso, MD, PhDAssociate ProfessorGynecologic Oncology DepartmentClinical Research UnitFondazione Policlinico Gemelli IRCCSRome, ItalyAlexandra Leary, MD, PhDMedical Oncologist and Team LeaderGynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:• Identifying patients who may benefit the most from adjuvant osimertinib  • Testing for EGFR mutations in early-stage NSCLC• Critical importance of getting molecular test results before starting immunotherapy• Monitoring cardiac toxicity in patients receiving osimertinib• Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinibPresenters:Ryan D. Gentzler, MD, MSAssociate ProfessorDivision of Hematology/OncologyDepartment of MedicineUniversity of VirginiaThoracic Medical OncologistUniversity of Virginia Comprehensive Cancer CenterCharlottesville, VirginiaJonathan Riess, MD, MSAssociate ProfessorDepartment of Internal Medicine/Hematology-OncologyUniversity of California, DavisMedical Director, Thoracic OncologyUniversity of California, Davis Comprehensive Cancer CenterSacramento, CaliforniaLink to full program: https://bit.ly/3DZGzSO   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.